PRDS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRDS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the three months ended in Jun. 2023, Pardes Biosciences spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $73.01 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Pardes Biosciences gained $73.01 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2023.
The historical data trend for Pardes Biosciences's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pardes Biosciences Annual Data | |||||||
Trend | Dec20 | Dec21 | Dec22 | ||||
Cash Flow from Investing | - | - | -137.02 |
Pardes Biosciences Quarterly Data | ||||||||||
Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Cash Flow from Investing | Get a 7-Day Free Trial | - | - | - | 14.41 | 73.01 |
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Pardes Biosciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:
Cash Flow from Investing | (A: Dec. 2022 ) | ||||
= | Purchase Of Property, Plant, Equipment | + | Sale Of Property, Plant, Equipment | + | Purchase Of Business |
= | 0 | + | 0 | + | 0 |
+ | Sale Of Business | + | Purchase Of Investment | + | Sale Of Investment |
+ | 0 | + | -138.201 | + | 1.18 |
+ | Net Intangibles Purchase And Sale | + | Cash From Discontinued Investing Activities | + | Cash From Other Investing Activities |
+ | 0 | + | 0 | + | 6.883382752676E-15 |
= | -137.02 |
Pardes Biosciences's Cash Flow from Investing for the quarter that ended in Jun. 2023 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $87.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pardes Biosciences (NAS:PRDS) Cash Flow from Investing Explanation
Cash flow from investing contains nine items:
1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.
Pardes Biosciences's purchase of property, plant, equipment for the three months ended in Jun. 2023 was $0.00 Mil. It means Pardes Biosciences spent $0.00 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.
Pardes Biosciences's sale of property, plant, equipment for the three months ended in Jun. 2023 was $0.00 Mil. It means Pardes Biosciences gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Pardes Biosciences's purchase of business for the three months ended in Jun. 2023 was $0.00 Mil. It means Pardes Biosciences spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Pardes Biosciences's sale of business for the three months ended in Jun. 2023 was $0.00 Mil. It means Pardes Biosciences gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Pardes Biosciences's purchase of investment for the three months ended in Jun. 2023 was $0.00 Mil. It means Pardes Biosciences spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Pardes Biosciences's sale of investment for the three months ended in Jun. 2023 was $73.01 Mil. It means Pardes Biosciences gained $73.01 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Pardes Biosciences's net Intangibles purchase and sale for the three months ended in Jun. 2023 was $0.00 Mil. It means Pardes Biosciences paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Pardes Biosciences's cash from discontinued investing activities for the three months ended in Jun. 2023 was 0.00 Mil. It means Pardes Biosciences paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Pardes Biosciences's cash from other investing activities for the three months ended in Jun. 2023 was $0.00 Mil. It means Pardes Biosciences paid $0.00 Mil for other investing activities.
Thank you for viewing the detailed overview of Pardes Biosciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Fs Development Holdings Ii, Llc | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Foresite Capital Opportunity Fund V, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Foresite Capital Fund V, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Sean P. Brusky | officer: Chief Commercial Officer | C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008 |
Thomas G Wiggans | director, officer: Chief Executive Officer | |
Foresite Capital Management V, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
Pottage John C Jr | director | ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511 |
Alsup Laurie Smaldone | director | 190 WOOSAMONSA RD, PENNINGTON NJ 08534 |
Heidi Henson | officer: Chief Financial Officer | 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008 |
J Jay Lobell | director | 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024 |
Brian Philippe Tinmouth | officer: Chief Business & Strategy Ofcr | 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548 |
Brian Kearney | officer: Chief Development Officer | C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008 |
Laura Hamill | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Lee D Arnold | officer: Chief Scientific Officer | C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013 |
Uri A Lopatin | director, officer: President and CEO | C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013 |
From GuruFocus
By Marketwired • 07-19-2023
By GuruFocusNews GuruFocusNews • 06-11-2022
By Business Wire • 07-21-2023
By PRNewswire • 08-01-2023
By sperokesalga sperokesalga • 02-21-2023
By Business Wire • 08-07-2023
By Marketwired • 07-21-2023
By Marketwired • 07-17-2023
By Marketwired • 08-31-2023
By sperokesalga sperokesalga • 02-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.